Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $73M (up 8.4% year over year) with net income of $32M.
Q3 2025 key financials · XBRL
- Revenue
- $73M
- +8.4% YoY · +4.9% QoQ
- Net income
- $32M
- +119.9% YoY · +46.7% QoQ
- Operating margin
- 40.5%
- EPS (diluted)
- $0.23
- +130.0% YoY · +43.8% QoQ
Source: XBRL data from the Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 10-Q on SEC EDGAR. USD.
Aurinia Pharmaceuticals Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New U.S. national security investigation on pharmaceutical imports may trigger tariffs or trade restrictions impacting supply chain from Switzerland
- Updated risk: potential retaliatory tariffs from Otsuka Territories on U.S. pharmaceutical imports could harm Otsuka's voclosporin sales and Aurinia's revenue
- Regulatory/legal risk: uncertain U.S. economic policy changes including pricing restrictions or export controls affecting cross-border pharmaceutical business
- Operational risk: reliance on international supply chain importing key ingredients into U.S. from Switzerland presents near-term disruption risk
- Financial risk: indirect exposure to trade policy impacts through revenue dependence on Otsuka's sales in international markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aurinia Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.